Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation

Inclusion Criteria: * Patients with confirmed diagnosis of acute myeloid leukemia according to the World Health Organization (WHO) classification (including de novo AML, t-AML and s-AML) * Presence of NPM1 mutation as assessed in one of the central AMLSG reference laboratories. * Age \> 60 years. There is no upper age limit. * No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis if needed for up to 10 days during the diagnostic screening phase. * Signed written informed consent * Men must give their informed consent that they do not father a baby and must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy. (while on therapy and for 3 month after the last dose of chemotherapy) * WHO performance status ≤ 3 * Patients not eligible for intensive chemotherapy according to at least one of the following criteria * HCT-CI Score \>2 * Patient's decision * age ≥ 75 years Exclusion Criteria: The presence of any of the following will exclude a patient from study enrollment: * All other AML subtypes, in particular those AML with other recurrent genetic changes (according to WHO 2008): * AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 * AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 * AML with t(15;17)(q22;q12); PML-RARA (or other translocations involving RARA) * AML with t(9;11)(p22;q23); MLLT3-MLL (or other translocations involving MLL) * AML with t(6;9)(p23;q34); DEK-NUP214 * AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 * No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and all other treating physicians about study participation * Bleeding disorder independent of leukemia * Uncontrolled infection * Known positive for HIV, HBV or HCV * Organ insufficiency (creatinine \>1.5x upper normal serum level; bilirubin, AST or ALP \>2.5x upper normal serum level, not attributable to AML; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder) * Severe neurological or psychiatric disorder interfering with ability of giving an informed consent * Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.